![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GAS2L3 |
Gene summary for GAS2L3 |
![]() |
Gene information | Species | Human | Gene symbol | GAS2L3 | Gene ID | 283431 |
Gene name | growth arrest specific 2 like 3 | |
Gene Alias | G2L3 | |
Cytomap | 12q23.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | A0A024RBF4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
283431 | GAS2L3 | HCC1_Meng | Human | Liver | HCC | 1.01e-48 | 1.85e-01 | 0.0246 |
283431 | GAS2L3 | HCC1 | Human | Liver | HCC | 9.07e-14 | 1.73e+00 | 0.5336 |
283431 | GAS2L3 | HCC2 | Human | Liver | HCC | 5.06e-30 | 2.82e+00 | 0.5341 |
283431 | GAS2L3 | HCC5 | Human | Liver | HCC | 9.82e-30 | 2.10e+00 | 0.4932 |
283431 | GAS2L3 | S027 | Human | Liver | HCC | 5.69e-08 | 7.16e-01 | 0.2446 |
283431 | GAS2L3 | S028 | Human | Liver | HCC | 9.40e-22 | 9.00e-01 | 0.2503 |
283431 | GAS2L3 | S029 | Human | Liver | HCC | 1.52e-07 | 5.72e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000701522 | Liver | HCC | actin filament organization | 252/7958 | 442/18723 | 3.83e-10 | 1.25e-08 | 252 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GAS2L3 | SNV | Missense_Mutation | c.1052N>C | p.Gly351Ala | p.G351A | Q86XJ1 | protein_coding | tolerated(0.54) | benign(0.001) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
GAS2L3 | SNV | Missense_Mutation | rs778139968 | c.920N>T | p.Ser307Leu | p.S307L | Q86XJ1 | protein_coding | tolerated(0.05) | benign(0.027) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GAS2L3 | SNV | Missense_Mutation | c.620G>A | p.Cys207Tyr | p.C207Y | Q86XJ1 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GAS2L3 | SNV | Missense_Mutation | novel | c.1073N>T | p.Ser358Leu | p.S358L | Q86XJ1 | protein_coding | deleterious(0.01) | possibly_damaging(0.454) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
GAS2L3 | SNV | Missense_Mutation | c.1612C>G | p.Gln538Glu | p.Q538E | Q86XJ1 | protein_coding | tolerated(0.07) | benign(0.084) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
GAS2L3 | SNV | Missense_Mutation | c.520N>A | p.Glu174Lys | p.E174K | Q86XJ1 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
GAS2L3 | SNV | Missense_Mutation | c.1999N>G | p.Ser667Gly | p.S667G | Q86XJ1 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GAS2L3 | SNV | Missense_Mutation | rs764425648 | c.364N>T | p.Arg122Trp | p.R122W | Q86XJ1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
GAS2L3 | SNV | Missense_Mutation | c.1112C>T | p.Ser371Phe | p.S371F | Q86XJ1 | protein_coding | deleterious(0) | possibly_damaging(0.671) | TCGA-AA-A02O-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GAS2L3 | SNV | Missense_Mutation | c.728G>A | p.Arg243Gln | p.R243Q | Q86XJ1 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AY-A71X-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |